- Home
- RUBI vs ADXN Comparison
RUBI vs ADXN Comparison
Compare RUBI & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUBI
- ADXN
- Stock Information
- Founded
- RUBI N/A
- ADXN 2002
- Country
- RUBI Marshall Islands
- ADXN Switzerland
- Employees
- RUBI N/A
- ADXN N/A
- Industry
- RUBI Marine Transportation
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- RUBI Consumer Discretionary
- ADXN Health Care
- Exchange
- RUBI Nasdaq
- ADXN Nasdaq
- Market Cap
- RUBI 10.9M
- ADXN 10.1M
- IPO Year
- RUBI N/A
- ADXN N/A
- Fundamental
- Price
- RUBI $2.70
- ADXN $7.85
- Analyst Decision
- RUBI
- ADXN Strong Buy
- Analyst Count
- RUBI 0
- ADXN 1
- Target Price
- RUBI N/A
- ADXN $30.00
- AVG Volume (30 Days)
- RUBI 1.5M
- ADXN 1.5K
- Earning Date
- RUBI 01-01-0001
- ADXN 08-19-2025
- Dividend Yield
- RUBI N/A
- ADXN N/A
- EPS Growth
- RUBI N/A
- ADXN N/A
- EPS
- RUBI N/A
- ADXN 0.10
- Revenue
- RUBI N/A
- ADXN $278,508.00
- Revenue This Year
- RUBI N/A
- ADXN $86.57
- Revenue Next Year
- RUBI N/A
- ADXN N/A
- P/E Ratio
- RUBI N/A
- ADXN $0.70
- Revenue Growth
- RUBI N/A
- ADXN N/A
- 52 Week Low
- RUBI $2.36
- ADXN $6.51
- 52 Week High
- RUBI $6.69
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- RUBI N/A
- ADXN 39.98
- Support Level
- RUBI N/A
- ADXN $8.01
- Resistance Level
- RUBI N/A
- ADXN $8.19
- Average True Range (ATR)
- RUBI 0.00
- ADXN 0.07
- MACD
- RUBI 0.00
- ADXN -0.02
- Stochastic Oscillator
- RUBI 0.00
- ADXN 9.81
About RUBI Rubico Inc. Common Stock
Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.